KalVista Pharmaceuticals, Inc.
KALV
$11.85
$0.100.85%
NASDAQ
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -60.10M | -52.23M | -48.51M | -42.27M | -40.44M |
| Total Depreciation and Amortization | 252.00K | 261.00K | 229.00K | 227.00K | 224.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10.04M | 62.00K | 10.01M | 2.19M | 2.31M |
| Change in Net Operating Assets | -4.70M | 11.54M | 5.59M | 213.00K | -2.31M |
| Cash from Operations | -54.50M | -40.36M | -32.68M | -39.64M | -40.22M |
| Capital Expenditure | -290.00K | -281.00K | -24.00K | -108.00K | -21.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 21.55M | -3.05M | 8.54M | 48.78M | 37.18M |
| Cash from Investing | 21.26M | -3.33M | 8.52M | 48.67M | 37.16M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.29M | 1.85M | 56.54M | 295.00K | 3.00M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 21.92M | 2.81M | 95.23M | -- | -- |
| Cash from Financing | 23.21M | 4.66M | 151.77M | 295.00K | 3.00M |
| Foreign Exchange rate Adjustments | 2.72M | 3.36M | -1.25M | 407.00K | 117.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -7.31M | -35.67M | 126.36M | 9.73M | 59.00K |